An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-536 in Patients With β-Thalassemia Previously Enrolled in Study A536-04

Trial Profile

An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-536 in Patients With β-Thalassemia Previously Enrolled in Study A536-04

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Luspatercept (Primary)
  • Indications Beta-thalassaemia
  • Focus Adverse reactions
  • Sponsors Acceleron Pharma
  • Most Recent Events

    • 25 Jun 2017 Results of long-term luspatercept treatment from base and extension study presented at the 22nd Congress of the European Haematology Association
    • 23 Jun 2017 Results from this trial published in an Acceleron Pharma Media Release.
    • 23 Jun 2017 According to an Acceleron Pharma media release, data from this trial were presented at the 22nd Congress of the European Hematology Association (EHA) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top